Evidence map›Paper›PMID 40611309›Full record

Trial reportAntimicrobial resistance and infection control2025

An economic evaluation of a hospital-wide bundle intervention to reduce hospital-acquired infections and bladder distension among hip fracture patients in Sweden.

Sneha Abdul Jabbar, Maria Frödin, Ewa Wikström, Brigid M Gillespie, Hanna Gyllensten, Annette Erichsen

Registry-linked trialAbstract readClinical Trial
In one paragraph

Trial report in Antimicrobial resistance and infection control, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02983136 (Safe Hands at the Sharp End- Implementing Aseptic Technique in the Operating Room, A Prospective Controlled Study With an Embedded Process Evaluation), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02983136 nacompletednot on this map

Safe Hands at the Sharp End- Implementing Aseptic Technique in the Operating Room, A Prospective Controlled Study With an Embedded Process Evaluation

TypeinterventionalSponsorGöteborg UniversityRan2015 to 2018Enrolled12ConditionsSurgical Wound InfectionArmsDialogue and inter-professional learning
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sneha Abdul JabbarSahlgrenska Academy, University of Gothenburg, Box 457, Gothenburg, SE-405 30, Sweden.
Maria FrödinInstitute of Health and Care Sciences, University of Gothenburg, Box 457, Gothenburg, SE-405 30, Sweden.
Ewa WikströmSchool of Business, Economics and Law, Department of Business Administration, University of Gothenburg, Västra Götalandregionen, Gothenburg, Sweden.
Brigid M GillespieNational Health and Medical Research Council Centre of Research Excellence in Wiser Wound Care, Queensland, Gold Coast, Australia.
Hanna GyllenstenInstitute of Health and Care Sciences, University of Gothenburg, Box 457, Gothenburg, SE-405 30, Sweden.
Annette ErichsenInstitute of Health and Care Sciences, University of Gothenburg, Box 457, Gothenburg, SE-405 30, Sweden. annette.erichsen@gu.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA theory-driven knowledge translation program was established to co-create and implement evidence-based practices to prevent urinary catheter-associated urinary tract infections (UC-UTIs) and bladder distension (BD). This study investigates the cost-effectiveness of implementing the Safe Hands and Safe Bladder bundle intervention compared to standard care for patients undergoing hip fracture surgery in Sweden.

methodThe study included outcomes from a quality register of patients who underwent hip fracture surgery at a Swedish hospital from 2015 to 2020. Adopting a healthcare perspective, estimates for the implementation cost were derived using activity-based costing, while the bundle's cost-effectiveness was estimated using a decision tree model. Health outcomes were evaluated based on adverse events, specifically UC-UTI and BD. Analyses included calculating the incremental cost-effectiveness ratio (ICER), which denotes the incremental cost per added infection rate expressed as a percentage. Additionally, sensitivity analyses were conducted to test the robustness of the results under alternative cost assumptions.

resultsThe likelihood of avoiding BD or UC-UTI increased from 50 to 87% over the course of the intervention year. The discounted implementation cost was SEK 890,389 (corresponding to Int$ 102,721). However, the implementation cost was offset by costs for a prolonged hospital stay due to these adverse events, resulting in an overall cost savings of SEK - 7,334 per patient (Int$ -846) in 2020 compared to before the intervention was introduced. Consequently, the intervention proved to be cost-effective, leading to savings and a decrease in the occurrence of adverse events.

conclusionImplementing the bundle intervention in units providing care for patients with acute hip fractures proved cost-effective. This offers decision makers valuable insights and demonstrates that implementation programs incorporating collaboration, facilitation and co-creation processes can effectively use limited resources. Further research should determine the generalizability of the findings to other settings and populations. CLINICALTRIALS: GOV REGISTRATION: NCT02983136 and ISRCTN 17,022,695, retrospectively registered after data collection were completed.

Indexed as

Catheter-Related InfectionsCross InfectionHip FracturesPatient Care BundlesUrinary Tract InfectionsAgedAged, 80 and overCost-Benefit AnalysisFemaleHospitalsHumansMaleSwedenAdverse eventsBladder distensionBundle interventionsCatheter-associated urinary tract infectionsCost-effectiveness analysisHospital-acquired infectionsImplementation costs

Identifiers

PMID40611309
PMCPMC12226840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.